CERN Accelerating science

Internal Note and Article
Report number	CERN-ACC-NOTE-2014-0019
Title	CERN-MEDICIS (MEDical Isotopes Collected from ISOLDE): A new facility
Author(s)	Augusto, Ricardo Manuel dos Santos (CERN) ; Buehler, Leo (HUG, Geneva) ; Lawson, Zoe (CERN) ; Marzari, Stefano (CERN) ; Stachura, Monika (CERN) ; Stora, Thierry (CERN)
Corporate Author(s)	CERN. Geneva. ATS Department
Collaboration	CERN-MEDICIS Collaboration
Publication	2014
Imprint	23 Jan 2014
Number of pages	13
In:	Appl. Sci. 4 (2014) 265-281
DOI	10.3390/app4020265
Subject category	Health Physics and Radiation Effects ; Nuclear Physics - Experiment
Accelerator/Facility, Experiment	CERN MEDICIS CERN ISOLDE
Project	CERN MEDICIS
Free keywords	CERN MEDICIS ; ISOLDE ; radioisotope ; radiolanthanides ; bioconjugates ; Targeted Radiotherapy ; Targeted Alpha Therapy (TAT); ; cancer
Abstract	About 50% of the 1.4GeV CERN’s protons are sent onto targets to produce radioactive beams by online mass separation at ISOLDE, for a wide range of studies in fundamental and applied physics. CERN-MEDICIS is a spin-off dedicated to R&D in life sciences and medical applications. It is located in an extension of the Class A building presently under construction. It will comprise laboratories to receive the irradiated targets from a new station located at the dump position behind the ISOLDE production targets. An increasing range of innovative isotopes will thus progressively become accessible from the start-up of the facility in 2015 onward; for fundamental studies in cancer research, for new imaging and therapy protocols in cell and animal models and for pre-clinical trials, possibly extended to specific early phase clinical studies up to phase I trials. 500 MBq isotope batches purified by electromagnetic mass separation combined with chemical methods will be collected on a weekly basis. Possible future upgrade with GBq pharmaceutical-grade (i.e., cGMP) batch production capabilities is finally presented.

Email contact: geraldine.saunier@cern.ch